Evaluation and Comparison of Treatment Response and In-Hospital Prognosis of COVID-19-Related Guillain-Barre Syndrome with Non-COVID-19 Patients
- PMID: 40486031
- PMCID: PMC12138670
- DOI: 10.47176/mjiri.39.34
Evaluation and Comparison of Treatment Response and In-Hospital Prognosis of COVID-19-Related Guillain-Barre Syndrome with Non-COVID-19 Patients
Abstract
Background: The coronavirus disease 2019 (COVID-19) outbreak has caused significant health and social impacts worldwide. Severe acute respiratory syndrome coronavirus 2, the virus responsible for COVID-19, can lead to neurological symptoms, including Guillain-Barré syndrome (GBS). This study aimed to compare the clinical manifestations, electrophysiological characteristics, degree of disability, and treatment outcomes of GBS patients with COVID-19 (COVID-19-related GBS) with GBS patients without COVID-19.
Methods: This retrospective cross-sectional multicenter study investigated the clinical characteristics and outcomes of GBS patients with a history of COVID-19. A total of 60 patients with GBS and a history of COVID-19 were included in the COVID-19 group, while 56 patients with GBS without COVID-19 were included in the control group. Demographic, clinical, therapeutic, and prognostic data were compared between the 2 groups.
Results: The COVID-19 patients were older (56.2 ± 16.8 vs 47.46 ± 19.25; P = 0.01), and there was no sex difference between the 2 groups. The most frequent electrophysiological type was acute inflammatory demyelinating polyradiculoneuropathy (55% and 41%) in both groups. Although almost half of the patients in both groups were admitted to the intensive care unit (ICU), the group of COVID-19 patients required mechanical ventilation more (16.6% vs 0%; P < 0.001). Also, the COVID-19 group had more length of ICU stay (P < 0.001). Although some electrophysiological differences were found (acute motor axonal neuropathy was more frequent in the non-COVID-19 group), The analysis did not show any difference in the response to treatment scores based on Phenotype, type of treatment, or electrophysiological pattern between the 2 groups of patients.
Conclusion: GBS in COVID-19 patients may have different manifestations and electrophysiological patterns, but the response to treatment and in-hospital prognosis were not different compared with GBS in non-COVID-19 patients.
Keywords: COVID-19; Guillain-Barré Syndrome; Prognosis.
© 2025 Iran University of Medical Sciences.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Clinical features and outcome of Guillain-Barre syndrome in Saudi Arabia: a multicenter, retrospective study.BMC Neurol. 2021 Jul 12;21(1):275. doi: 10.1186/s12883-021-02314-5. BMC Neurol. 2021. PMID: 34253174 Free PMC article.
-
Clinical features and real-world outcomes of Guillain-Barré syndrome in the Philippines.Neurol Res. 2021 Dec;43(12):995-1004. doi: 10.1080/01616412.2021.1948750. Epub 2021 Jul 6. Neurol Res. 2021. PMID: 34229572
-
Clinical, electrophysiological findings and evaluation of prognosis of patients with Guillain-Barré syndrome.Turk J Pediatr. 2019;61(2):200-208. doi: 10.24953/turkjped.2019.02.008. Turk J Pediatr. 2019. PMID: 32077646
-
Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barré syndrome?Eur J Med Res. 2023 Feb 25;28(1):98. doi: 10.1186/s40001-023-01055-0. Eur J Med Res. 2023. PMID: 36841799 Free PMC article. Review.
-
Guillain-Barré syndrome associated with COVID-19: A systematic review.Brain Behav Immun Health. 2023 Mar;28:100578. doi: 10.1016/j.bbih.2022.100578. Epub 2023 Jan 17. Brain Behav Immun Health. 2023. PMID: 36686624 Free PMC article. Review.
References
-
- Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021 Mar 27;397(10280):1214–1228. - PubMed
LinkOut - more resources
Full Text Sources